CHD/Prevention News

Caffeine intake equivalent to about six cups of coffee per day was associated with prolonged increases in blood pressure and heart rate up to 5 minutes after physical activity, researchers reported.

Text messages delivered to patients’ smartwatches show promise to improve physical activity for those undergoing cardiac rehabilitation, but sustained behavioral change over time may remain a challenge, researchers reported.

Adults with type 2 diabetes who are referred to a clinical pharmacist are more likely to meet their HbA1c goal and receive appropriate medication management of comorbidities than people receiving usual care, according to a presenter.

HU6, a controlled metabolic accelerator, met the primary endpoint of weight reduction in patients with obesity-related heart failure with preserved ejection fraction, according to top-line results of the phase 2a HuMAIN trial.

Bariatric surgery did not reduce risk for obesity-related cancer or cardiovascular disease compared with nonoperative treatment among adults aged at least 60 years, according to results of a population-based cohort study.

Dietary acid reduction from fruits and vegetables or sodium bicarbonate improved kidney health in patients with hypertension and macroalbuminuria, findings from a randomized controlled trial showed.

SGLT2 inhibitors were associated with similar renal and CV outcomes vs. GLP-1 receptor agonists for patients with diabetes, regardless of chronic kidney disease status, researchers reported.

In an analysis of more than 3 million U.S. adults, most patients with a class 1a recommendation for SGLT2 inhibitors were not prescribed them, researchers reported in the Journal of the American College of Cardiology.

Adults with type 2 diabetes have lower risks for death and major adverse cardiovascular and kidney events if they use tirzepatide compared with GLP-1 receptor agonists, according to observational data published in JAMA Network Open.

Erythritol, a nonnutritive sweetener generally recognized as safe by the FDA, demonstrated fast-acting prothrombotic properties not observed with traditional glucose in a small study.